Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

MLA

Seymour, John F., et al. “Association of Early Disease Progression and Very Poor Survival in the GALLIUM Study in Follicular Lymphoma: Benefit of Obinutuzumab in Reducing the Rate of Early Progression.” Haematologica, vol. 104, no. 6, June 2019, pp. 1202–08. EBSCOhost, https://doi.org/10.3324/haematol.2018.209015.

APA

Seymour, J. F., Marcus, R., Davies, A., Gallop-Evans, E., Grigg, A., Haynes, A., Herold, M., Illmer, T., Nilsson-Ehle, H., Sökler, M., Dünzinger, U., Nielsen, T., Launonen, A., & Hiddemann, W. (2019). Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica, 104(6), 1202–1208. https://doi.org/10.3324/haematol.2018.209015

Chicago

Seymour, John F, Robert Marcus, Andrew Davies, Eve Gallop-Evans, Andrew Grigg, Andrew Haynes, Michael Herold, et al. 2019. “Association of Early Disease Progression and Very Poor Survival in the GALLIUM Study in Follicular Lymphoma: Benefit of Obinutuzumab in Reducing the Rate of Early Progression.” Haematologica 104 (6): 1202–8. doi:10.3324/haematol.2018.209015.